奥图穆马
医学
不利影响
耐火材料(行星科学)
免疫疗法
治疗效果
效价
内科学
抗体效价
脑炎
CD20
免疫学
抗体
胃肠病学
免疫系统
病毒
物理
天体生物学
作者
Qinming Zhou,Dou Yin,Jian-Fang Ma,Sheng Chen
标识
DOI:10.1016/j.jneuroim.2023.578062
摘要
The management of autoimmune encephalitis (AE) with immunotherapy is non-standardized, especially in refractory AE. Ofatumumab (OFA), an anti-CD20 antibody, has not been reported in the treatment of AE. This study presented three AE cases that received the OFA treatment. OFA was administered subcutaneously at a dose of 20 mg two or three times within three weeks. There were some mild adverse effects, including low-grade fever and dizziness. They had favorable responses (reduced antibody titer and clinical symptom improvement). Their symptoms were stable and even improved during a three-month follow-up. Thus, OFA injection is demonstrated to be safe and effective in treating AE. This is the first report about OFA treatment in AE, depicting its potential as a therapeutic option.
科研通智能强力驱动
Strongly Powered by AbleSci AI